BioStock: Capital injection sets Evaxion Biotech up for phase IIb trials

The third quarter of 2021 became a quite eventful one for Danish Evaxion Biotech that went public on the Nasdaq Capital Market in the US earlier this year. Backed by promising phase I/IIa results with its main drug candidate EVX-01 the company targets phase IIb trials this winter. To prepare for the next step on the journey, 27.6 MUSD was recently raised in a follow-on public offering.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/11/capital-injection-sets-evaxion-biotech-up-for-phase-iib-trials/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Subscribe

Documents & Links

Quick facts

BioStock: Capital injection sets Evaxion Biotech up for phase IIb trials
Tweet this